Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells by unknown
POSTER PRESENTATION Open Access
Glioma microenvironment-derived CCL2
recruits regulatory T cells and myeloid-derived
suppressor cells
Alan L Chang1*, Jason Miska1, Derek A Wainwright2, Mahua Dey1, Jian Qiao1, Peter Pytel1, Yu Han1,
Lingjiao Zhang1, Irina V Balyasnikova1, Atique U Ahmed1, Maciej S Lesniak1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Glioblastoma multiforme (GBM) is the most common
malignant primary brain tumor in adults with a median
survival of 14.6 months despite surgery, radiotherapy,
and chemotherapy. One hallmark of GBM is the accu-
mulation of potently immunosuppressive regulatory
T cells (Tregs) and myeloid-derived suppressor cells
(MDSCs). However, the factors underlying Treg and
MDSC trafficking to GBM have not been well estab-
lished. We identified C-C motif chemokine 2 (CCL2) as
a glioma microenvironment-derived chemokine that
recruits Tregs and MDSCs that express the cognate
receptors CCR4 and CCR2, respectively. First, we found
that CCL2 expression is a prognostic factor for GBM
patients using data from The Cancer Genome Atlas.
High CCL2 expression was correlated with a poor prog-
nosis in both univariate and multivariate Cox regression
analyses. We also confirmed the presence of CCL2 in
GBM patient samples by immunohistochemical staining.
In the syngeneic murine GL261 model of GBM, the
major source of CCL2 was macrophages and microglia
in the glioma microenvironment rather than tumor cells
themselves. Treatment of ex vivo isolated microglia and
bone marrow (BM)-derived macrophages with GL261
conditioned media resulted in CCL2 production, sug-
gesting that a soluble GL261-derived factor was respon-
sible for the production of CCL2 in microglia and
macrophages. To identify potential candidates for this
GL261-derived factor, a cytokine array was performed.
We found that CCL20 was highly produced by the
tumors and was sufficient for the stimulation of CCL2
production by BM-derived macrophages. Implantation
of GL261 cells in Ccl2-/- mice resulted in reduced levels of
Tregs and Ly-6C+ monocytic MDSCs but not Ly-6G+
granulocytic MDSCs. Finally, treatment of mice bearing
intracranial GL261 tumors with the small molecule che-
mokine receptor antagonist C 021 increased median survi-
val ~30%. Thus, the CCL2 chemokine-receptor axis is a
potential therapeutic target in GBM as a major mechan-
ism for the recruitment of Tregs and MDSCs.
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